Nini kilitokea
Basecamp Research, a London-based AI drug discovery company, announced a $140 million Series C funding round on September 23, 2026. The round, led by S32 with participation from Anthropic’s Anthology Fund and NVIDIA, will fund the training of next-generation EDEN models and the advancement of its AI-designed therapeutics . The company also appointed Richard Pearce as Chief Business Officer to expand pharmaceutical partnerships.
Basecamp Research announced a $140 million Series C financing on September 23, 2026, led by S32. The round included participation from Anthropic’s Anthology Fund, NVIDIA, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI, and True Ventures. Additional investment came from senior industry leaders, including André Hoffmann, Vice-Chairman of Roche.
The funding will be used to train a new generation of the company’s EDEN models and advance its AI-designed therapeutics toward clinical development. Basecamp also appointed Richard Pearce, formerly of Biogen, as Chief Business Officer to support the expansion of its pharmaceutical partnerships. Andy Conrad, General Partner at S32 and former CEO of Google’s Verily, joined the company’s Board of Directors.
Basecamp’s platform centers on EDEN, a biological applied to in vivo cell therapy. The company describes EDEN as a 28B- model trained on the Trillion Gene Atlas, a proprietary dataset containing over 100 billion novel genes at over 100T tokens. The Atlas was built with partners including NVIDIA, Anthropic, PacBio, and Ultima Genomics, drawing on biological data from more than 30 countries.
The company stated that EDEN models can produce potential therapeutic candidates directly from disease information, including designing cell and gene therapies, enzymes, and peptides. Basecamp reported that in wet-lab validation, EDEN showed zero-shot activity in primary human T-cells and achieved a 97% hit rate for designed antimicrobial peptides against priority pathogens.
Maelezo ya chanzo: unite.ai ↗
Kwa nini ni muhimu
This significant funding round validates the commercial and scientific potential of using large-scale biological foundation models for drug discovery. By investing in the training of EDEN models and expanding its proprietary Trillion Gene Atlas dataset, Basecamp aims to accelerate the development of personalized cell and gene therapies. The involvement of major tech and pharma investors signals a growing convergence of AI infrastructure and biotechnology, potentially reducing the time and cost associated with traditional drug discovery processes while enabling more complex therapeutic designs.
The $140 million investment represents a major commitment to AI-driven drug discovery, specifically focusing on the training of large-scale biological foundation models. This move underscores the industry's shift toward using AI to handle the complexity of genomic data and therapeutic design, which traditional methods struggle to address efficiently.
By integrating with Anthropic’s Claude Science and leveraging NVIDIA’s infrastructure, Basecamp is positioning itself at the intersection of general-purpose AI and specialized biotechnology. This collaboration suggests that AI models are becoming essential tools for scientific discovery, capable of generating novel biological insights and therapeutic candidates that can be validated in the lab.
The focus on in vivo cell therapy aims to overcome the high costs and manufacturing complexities of current cell therapies. If successful, Basecamp’s approach could make advanced genetic treatments more accessible and customizable, potentially transforming the treatment landscape for diseases like cancer and autoimmune disorders.
The involvement of diverse investors, including pharma executives and tech giants, indicates a broad consensus on the value of AI in biotech. This funding will likely accelerate the pace of research and development, potentially leading to earlier clinical trials and new standards for AI-assisted drug design.
Mbinu shirikishi: Jinsi Inavyofanya Kazi Kweli
Chunguza teknolojia msingi nyuma ya ukuzaji huu kwa maingiliano.
In AI, what are a model's "parameters"?
Nini cha kutazama baadaye
Monitor the clinical progression of Basecamp’s AI-designed therapeutics, particularly the in vivo cell therapies targeting cancer and autoimmune diseases. Watch for the release of new EDEN model versions and any updates to the Trillion Gene Atlas dataset. Additionally, track the expansion of pharmaceutical partnerships and the practical deployment of EDEN’s capabilities through Anthropic’s Claude Science platform.
The next phase of clinical development for Basecamp’s AI-designed therapeutics, particularly the in vivo cell therapies targeting cancer and autoimmune diseases, will be a key indicator of the platform’s real-world efficacy.
Updates to the EDEN models and the Trillion Gene Atlas dataset will reveal how the company is scaling its biological AI capabilities. The expansion of the dataset to include genomic data from more than 100 million species could significantly enhance the model’s ability to recognize patterns across diverse biological systems.
The expansion of pharmaceutical partnerships, led by the new Chief Business Officer, will determine how quickly Basecamp’s AI-designed candidates can move into broader clinical trials and commercialization.
The practical deployment of EDEN’s capabilities through Anthropic’s Claude Science platform will be closely watched, as it represents a direct integration of specialized biological AI into a widely used research tool, potentially accelerating discovery for other scientists and institutions.